Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery. 5-year results of the Zilver PTX randomized trial. Circulation 2016; 133: 1472-1483.

Published: 21st September 2016

Authors: Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB et al.

Conclusion

Some 474 patients were included. At five years, use of a drug eluting stent improved patency from 43.4 to 66.4 per cent (P<0.01) and clinical benefit from 59.3 to 79.8 per cent (P<0.01).

Pubmed Link

Your comments

0 Comments